Dobutamine

DEA Class;  Rx

Common Brand Names; 

  • Inotropic Agents

Parenteral direct-acting inotrope
Used for short-term treatment of patients with cardiac decompensation due to depressed contractility from organic heart disease or cardiac surgical procedures
Comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects

Indicated for the short-term inotropic treatment of low output states caused by congestive heart failure, cardiogenic shock, septic shock, or after cardiac surgery.

For use in coronary artery disease diagnosis† (i.e., dobutamine stress echocardiography).

Hypersensitivity to drug or components

Idiopathic hypertrophic subaortic stenosis

  • Tachyarrhythmia (~10%)
  • Hypertension (7.5%)
  • Eosinophilic myocarditis (≤7%)
  • Premature ventricular beats (5%; dose related)
  • Angina (1-3%)
  • Dyspnea (1-3%)
  • Fever (1-3%)
  • Headache (1-3%)
  • Nausea (1-3%)
  • Palpation (1-3%)
  • Cardiac dysrhythmia
  • Exacerbation of coronary arteriosclerosis
  • Hypokalemia
  • Injection-site reactions
  • Syncope

To optimize hemodynamics, correct hypovolemia if needed

Clinical experience with dobutamine following myocardial infarction has been insufficient to establish safety of drug for this use; there is concern that any agent that increases contractile force and heart rate may increase size of infarction by intensifying ischemia, but not known whether dobutamine does so

Severe coronary artery disease (CAD)

Hypertension common; hypotension may also occur

May cause a marked increase in heart rate or blood pressure,especially systolic pressure; because dobutamine facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response; in patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine; patients with pre-existing hypertension appear to face an increased risk of developing an exaggerated pressure response

During administration of dobutamine, monitor blood pressure continuously; pulmonary wedge pressure and cardiac output should be monitored whenever possible to aid safe and effective infusion of dobutamine in 5% dextrose Injection, USP

Ventricular ectopy exacerbation may occur

Pregnancy category: B

Lactation: Unknown whether drug is excreted into breast milk; avoid use

Adults

20 mcg/kg/minute IV infusion; rarely, up to 40 mcg/kg/minute IV per manufacturer.

Geriatric

20 mcg/kg/minute IV infusion; rarely, up to 40 mcg/kg/minute IV per manufacturer.

Adolescents

20 mcg/kg/minute IV infusion; rarely, up to 40 mcg/kg/minute IV per manufacturer.

Children

20 mcg/kg/minute IV infusion; rarely, up to 40 mcg/kg/minute IV per manufacturer.

Infants

20 mcg/kg/minute IV infusion; rarely, up to 40 mcg/kg/minute IV per manufacturer.

Neonates

20 mcg/kg/minute IV infusion is the usual maximum dosage; however, higher doses may be required in some clinical situations.

Dobutamine hydrochloride

infusion solution, in D5W

  • 100mg/100mL
  • 200mg/100mL
  • 400mg/100mL

injectable solution

  • 12.5mg/mL

About the Author

You may also like these

0